Antitumour activity of DX-8951f: a new camptothecin derivative

Bibliography

• WALL ME, WANT MC, COOK CE et al.: Plant antitumoragents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. (1966) 83:3888–3890.
   Google Scholar
• HSIANG YH, HERTZBERG R, HECHT S, LIU LF: Campto-thecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. (1985) 260:14873–14878.
   PubMed Web of Science ®Google Scholar
• MUGGIA FM, CREAVEN PJ, HANSEN HH, COHEN MH, SE-LAWRY OS: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correla-tion with preclinical studies. Cancer Chemother. Rep. (1972) 56:515–521.
   PubMedGoogle Scholar
• MOERTEL CG, SCHUTT AJ, REITEMEIER RJ, HAHN RG:Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. (1972) 56:95–101.
   PubMedGoogle Scholar
• KUNIMOTO T, NITTA K, TANAKA T et al.: Antitumor ac-tivity of 7-ethy1-1044-(1-piperidino)-1-piperidinolcar-bo nyloxy campt ot he cin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. (1987) 47:5944–5947.
   PubMed Web of Science ®Google Scholar
• TSURUO T, MATSUZAKI T, MATSUSHITA T, SAITO H, YO-KOKURA T: Antitumor effect of CPT-11, a new deriva-tive of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Che-mother. Pharmacol. (1988) 21:71–74.
   PubMed Web of Science ®Google Scholar
• KAWATO Y, FURUTA T, AONUMA M et al: Antitumor ac-tivity of a camptothecin derivative, CPT-11, against hu-man tumor xenografts in nude mice. Cancer Chemother. Pharmacol (1991) 28:192–198.
   PubMed Web of Science ®Google Scholar
• BURRIS HA III, HANAUSKE AR, JOHNSON RK et al.: Activ-ity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. Natl. Cancer Inst. (1992) 84:1816–1820.
   PubMed Web of Science ®Google Scholar
• HOUGHTON PJ, CHESHIRE PJ, MYERS L et al.: Evaluationof 9-dimethylaminomethy1-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol. (1992) 31:229–239.
   PubMed Web of Science ®Google Scholar
• SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RC, KAUFMANN SH: The current status of camptothecin analogues as antitumor agents. J. Nail Cancer Inst. (1993) 85:271–291.
   PubMed Web of Science ®Google Scholar
• OHNO R, OKADA K, MASAOKA T et al.: An early phase IIstudy of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. On-col. (1990) 8:1907–1912.
   PubMed Web of Science ®Google Scholar
• KANZAWA F, SUGIMOTO Y, MINATO K et al.: Establish-ment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: charac-terization and mechanism of resistance. Cancer Res. (1990) 50:5919–5924.
   PubMed Web of Science ®Google Scholar
• SCHILLER JH, KIM K, JOHNSON D: Phase II study of topo-tecan in extensive stage small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1994) 13:330.
   Google Scholar
• ARDIZZONI A, HANSEN H, DOMBERNOWSKY P et al: Phase II study of topotecan in pretreated small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (1994) 13:336.
   Google Scholar
• KUDELKA A, EDWARDS C, FREEDMAN R et al: An open phase II study to evaluate the efficacy of topotecan ad-ministered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carci-noma. Proc. Am. Soc. Clin. Oncol. (1993) 12:259.
   Google Scholar
• KAWATO Y, TERASAWA H: Recent advances in the me-dicinal chemistry and pharmacology of camptothecin. Prog. Med. Chem. (1997) 34:69–109.
   Google Scholar
• LIU LF, MILLER KG: Eukaryotic DNA topoisomerases, two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc. Natl. Acad. Sci. USA (1981) 78:3487–3491.
   PubMed Web of Science ®Google Scholar
• TANIZAWA A, KOHN KW, KOHLHAGEN G et al.: Differ-ential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Bio-chemistry (1995) 34:7200–7206.
   Google Scholar
• OHMORI T, PODACK ER, NISHIO K et al.: Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bc1-2. Biochem. Biophys. Res. Commun. (1993) 192:30–36.
   PubMed Web of Science ®Google Scholar
• MITSUI I, KUMAZAWA E, HIROTA Y et al.: A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vi-tro and in vivo. Jpn. J. Cancer Res. (1995) 86:776–782.
   PubMedGoogle Scholar
• ••First report of the in vitro cytotoxicity and in vivo antitumouractivity of DX-8951f.
   Google Scholar
• JOTO N, ISHII M, MINAMI M et al: DX-8951f, a water- soluble camptothecin analog, exhibits potent antitu-mor activity against a human lung cancer cell line and its SN-38-resistant variant. Int. J. Cancer (1997) 72:680–686.
   PubMed Web of Science ®Google Scholar
• ••A report on the mechanism of resistance of an SN-38-resistant variant and the action of DX-8951f against the variant.
   Google Scholar
• TAKIGUCHI S, KUMAZAWA E, SHIMAZOE T, TOHGO A, KONO A: Antitumor effect of DX-8951, a novel campto-thecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Jpn. J. Cancer Res. (1997) 88:760–769.
   PubMedGoogle Scholar
• •A report on the in vitro and in vivo antitumour activity of DX-8951f against human pancreatic cells.
   Google Scholar
• SHIMOYAMA M: The quantative measurement of cyto-cidal actions of alkylating agents and anticancer anti-biotics against in vitro cultured Yoshida ascites sarcoma. J. Jap. Soc. Cancer Ther. (1975) 10:63–72.
   PubMedGoogle Scholar
• SHIMOYAMA M: The quantative measurement of cyto-cidal actions of antimetabolites, Vinca alkaloids and L-asparaginase against in vitro cultured Yoshida as-cites sarcoma. J. Jap. Soc. Cancer Ther. (1975) 10:195–201.
   PubMedGoogle Scholar
• SHIMOYAMA M: Implication of cell-kill-kinetics of anti-cancer agents in the design of optimal therapeutic schedules. Can To Kagaku Ryoho (1976) 3:1103–1110.
   Google Scholar
• SKIPPER HE, SCHABEL FM, MELLET LB et al.: Implications of biochemical, cytokinetic, pharmacologic and toxi-cologic relationships in the design of optimal thera-peutic schedules. Cancer Chemother. Rep. (1970) 54:431–450.
   PubMedGoogle Scholar
• CHEN C-J, CHIN JE, UEDA K et al.: Internal duplicationand homology with bacterial transport proteins in the mdr 1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 47:381-389. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(4)
   Google Scholar
• GERLACH JH, ENDICOTT JA, JURANKA PF et al: Homol-ogy between P-glycoprotein and a bacterial haemo-lysin transport protein suggests a model for multidrug resistance. Nature (1986) 324:485–489.
   PubMed Web of Science ®Google Scholar
• TSURUO T: Mechanism of multidrug resistance and im-plications for therapy. Jpn. J. Cancer Res. (1988) 79:285–296.
   PubMedGoogle Scholar
• CHEN AY, YU C, POTMESIL M et al.: Camptothecin over-comes MDR1-mediated resistance in human KB carci-noma cells. Cancer Res. (1991) 51:6039–6044.
   PubMed Web of Science ®Google Scholar
• HENDRICKS CB, ROWINSKY EK, GROCHOW LB, DON-CHOWER RC, KAUFMANN SH: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of to-potecan (SK&F 104864), a new camptothecin ana-logue. Cancer Res. (1992) 52:2268–2278.
   PubMed Web of Science ®Google Scholar
• TAKEDA S, SHIMAZOE T, SATO K et al.: Differential ex-pression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tu-mor cell lines, detected by RNA/PCR-based quantita-tion assay. Biochem. Biophys. Res. Commun. (1992) 184:618–625.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO Y, TSUKAHARA S, OH-HARA T, ISOE T, TSU-RUO T: Decreased expression of DNA topoisoimerase I in camptothecin resistant tumor cell lines as deter-mined by a monoclonal antibody. Cancer Res. (1990) 50:6925–6930.
   PubMed Web of Science ®Google Scholar
• NAGAI S, YAMAUCHI M, ANDOH T et al: Establishment and characterization of human gastric and colonic xe-nograft lines resistant to CPT-11 ( a new derivative of camptothecin). j Surg. Oncol. (1995) 59:116–124.
   PubMed Web of Science ®Google Scholar
• KUBOTA N, OHTA S, TAKEDA Y et al.: Detection of topoi-somerase I gene mutation in CPT-11 resistant lung can-cer cell line. Biochem. Biophys. Res. Commun. (1992) 188:571–577.
   PubMed Web of Science ®Google Scholar
• AOGI K, NISHIYAMA M, HIRABAYASHI N et al: Establish-ment of a new multidrug-resistant cell line induced by continuous exposure to CPT-11. Proc. Am. Assoc. Cancer Res. (1994) 35:451.
   Google Scholar
• OGASAWARA H, NISHIO K, KANZAWA F eta].: Intracellu-lar carboxyl esterase activity is a determinant of cellu-lar sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn. J. Can-cer Res. (1995) 86:124–129.
   Google Scholar
• MITSUI I, OHSUKI S, HIROTA Y et al.: High potency of a camptothecin derivative DX-8951 might be attributed to good membrane permeability. Proc. Am. Assoc. Can-cer Res. (1994) 35:455.
   Google Scholar
• NEGORO S, FUKUOKA M, MASUDA N et al.: Phase I study of weekly intravenous infusions of CPT-11, a new de-rivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Nati Cancer Inst. (1991) 83:1164–1168.
   PubMed Web of Science ®Google Scholar
• KANEDA N, NAGATA H, FURUTA T, YOKOKURA T: Me-tabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mice. Cancer Res. (1990) 50:1715–1720.
   PubMed Web of Science ®Google Scholar
• ROTHENBERG ML, ROWINSKY EK, KUHN JG et al: Clini-cal trials and pharmacokinetic studies of CPT-11 in the United States. In: Camptothecins: New Anticancer Agents. Potmesil M, Pinedo H (Eds.), CRC Press, Boca Raton, FL, USA (1995):75–81.
   Google Scholar
• ROWINSKY EK, GROCHOW LB, HENDRICKS CB et al.:Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol. (1992) 10:647–656.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, BERAN M, ELLIS A et al.: Phase I study of topotecan, a new topoisomerase I inhibitor, in pa-tients with refractory or relapsed acute leukemia. Blood (1993) 81:1146–1151.
   PubMed Web of Science ®Google Scholar
• HOCHSTER H, LIEBES L, SPEYER J et al.: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol. (1994) 12:553–559.
   PubMed Web of Science ®Google Scholar
• PRATT CB, STEWART C, SANTANA VM eta].: Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Gun. Oncol. (1994) 12:539–543.
   Google Scholar
• VAN WARMERDAM LJC, TEN BOKKEL HUININK WW, RO-DENHUIS S et al.: Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continu-ous infusion. J. Clin. Oncol. (1995) 13:1768–1776.
   Google Scholar
• KUMAZAWA E, OCHI Y, NAKAYAMA Y et al.: Antitumor effect of DX-8951, a new camptothecin derivative, in various murine models. Proc. Am. Assoc. Cancer Res. (1995) 36:440.
   Google Scholar
• •This paper reports on the antitumour activity of DX-8951f with various regimens and doses.
   Google Scholar
• KUMAZAWA E, JIMBO T, OCHI Y, TOHGO A: Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tu-mors xenografted in nude mice. Cancer Chemother. Pharmacol. (In Press.)
   Google Scholar
• ••A report on the antitumour activity of DX-8951f against vari-ous human tumours xenografted in nude mice.
   Google Scholar
• FUJITA F, FUJITA M, TAGUCHI T et al.: Multifactorial analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice. Int. J. Cancer (1989) 43:637–644.
   PubMed Web of Science ®Google Scholar